國家衛生研究院 NHRI:作者相关文件
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 861819      在线人数 : 801
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版

    类别浏览

    正在载入社群分类, 请稍候....

    年代浏览

    正在载入年代分类, 请稍候....

    "Kang, YK"的相关文件  

    回到依作者浏览

    显示 30 项.

    类别 日期 题名 關聯 档案
    [陳立宗] 會議論文/會議摘要 2021-05 Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) -
    [陳立宗] 會議論文/會議摘要 2020-09 Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study -
    [陳立宗] 會議論文/會議摘要 2020-02 A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data -
    [陳立宗] 會議論文/會議摘要 2019-02 Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2 -
    [陳立宗] 會議論文/會議摘要 2018-09 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials -
    [陳立宗] 會議論文/會議摘要 2018-05 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials -
    [陳立宗] 會議論文/會議摘要 2018-02 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials -
    [陳立宗] 會議論文/會議摘要 2017-09 ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer -
    [陳立宗] 會議論文/會議摘要 2017-09 ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer -
    [陳立宗] 會議論文/會議摘要 2017-09 Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37) -
    [陳立宗] 會議論文/會議摘要 2017-09 A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) -
    [陳立宗] 會議論文/會議摘要 2017-02 Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial -
    [陳立宗] 會議論文/會議摘要 2014-01 EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib -
    [陳立宗] 期刊論文 2024-08-20 Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri -
    [陳立宗] 期刊論文 2022-04 Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials -
    [陳立宗] 期刊論文 2022-02 Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr -
    [陳立宗] 期刊論文 2022-01 Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study -
    [陳立宗] 期刊論文 2021-07 Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab -
    [陳立宗] 期刊論文 2020-05 A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data -
    [陳立宗] 期刊論文 2020-01 Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer -
    [陳立宗] 期刊論文 2019-03 A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens -
    [陳立宗] 期刊論文 2019-02 Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4) -
    [陳立宗] 期刊論文 2017-12 Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial -
    [陳立宗] 期刊論文 2017-10 Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review -
    [陳立宗] 期刊論文 2016-10 Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor -
    [陳立宗] 期刊論文 2016-08 Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma -
    [陳立宗] 期刊論文 2014-07-02 Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial -
    [陳立宗] 期刊論文 2013-12 Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma -
    [陳立宗] 期刊論文 2013-11 Management of gastric cancer in Asia: Resource-stratified guidelines -
    [陳立宗] 期刊論文 2013-06-21 A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈